Open Menu Close Menu Open Search Close Search Open Directory Close Directory

Monitoring of dogs treated for immune-mediated hemolytic anemia (IMHA)

Pharmacodynamic monitoring of dogs treated for immune-mediated hemolytic anemia (IMHA)

Status: Recruiting

Species: Dog

Veterinary Speciality: Emergency Critical Care, Internal Medicine

Description

Immune-mediated hemolytic anemia (IMHA) is an important disease in dogs that causes anemia (a low red blood cell count). We would like to be able to identify how a patient is responding to therapy using a blood test.  We hope to identify how long it takes to see suppression of the immune markers in a blood sample during therapy and see if this varies by treatment regimen used.  We will be looking at three different  lymphocyte responses during treatment for IMHA. Our goal is to identify if one of these markers decreases more rapidly in response to immunosuppressive treatment, and if one treatment is best associated with patient survival at 1 month.

Inclusion Criteria

Dogs diagnosed with immune-mediated hemolytic anemia weighing more than 6 kg.

Exclusion Criteria

As part of the study, you will receive a free 2 and 4 week recheck with our Internal Medicine service. Cost of the blood draw will be covered by the study, as will the cost of the recheck red blood cell test (PCV).

Contact Info

For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

Print Friendly, PDF & Email